Bristol Myers, GentiBio ink up to $1.9B pact to develop therapies for inflammatory bowel diseases

Aug. 10, 2022 7:25 AM ETBristol-Myers Squibb Company (BMY)By: Ravikash, SA News Editor

Stock Markets Open One Day After Steep Drop Over Apple"s Revised Forecast

Drew Angerer/Getty Images News

  • Bristol Myers Squibb (NYSE:BMY) is collaborating with GentiBio to develop regulatory T cell (Treg) therapies for inflammatory bowel diseases (IBD).
  • Under the multi-year collaboration, GentiBio will use its modular engineered Treg platform and scalable manufacturing process to produce stable and disease-specific engineered Tregs against multiple targets.
  • Bristol Myers will have the right to develop and advance up to three of the resulting programs into clinical trials.
  • Bristol Myers paid GentiBio an undisclosed cash amount upfront. In addition, GentiBio is eligible to receive development and sales milestone payments of up to $1.9B and royalties.
  • "Tregs have demonstrated the potential to suppress inflammation and autoimmune dysfunction in a tissue-restricted manner, thus avoiding widespread, and potentially harmful, immune suppression," said Robert Plenge, Bristol Myers' senior vice president and head, Immunology, Cardiovascular and Fibrosis Thematic Research Center and head, Translational Medicine.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.